| Donald Randolph Mckinley, MD | |
|
4300 Fayetteville Rd, Lumberton, NC 28358-2677 | |
| (910) 608-3078 | |
| (910) 608-3079 |
| Full Name | Donald Randolph Mckinley |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 42 Years |
| Location | 4300 Fayetteville Rd, Lumberton, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689664336 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 0101034676 (Virginia) | Secondary |
| 207V00000X | Obstetrics & Gynecology | 2013-01534 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Southeastern Regional Medical Center | Lumberton, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Unc Physicians Network | 5496940546 | 709 |
News Archive
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.
In the German Center for Infection Research (DZIF), scientists from the universities of Tübingen, Münster and Munich join forces and prepare together with the company Hyglos clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: A highly effective protein from bacteria-specific viruses, so-called bacteriophages, shall rapidly kill the bacteria, which frequently occur in the nose.
The Posey Company, a leader in the design and manufacture of innovative and reliable patient safety solutions, today officially announced the availability of the Posey StaySafe(TM) Bed, Model 8080, for European markets. The bed has been designed for sale in Holland, France, and Germany; sales to additional European country markets will follow.
One of the most innovative biotechnologies of the last decade has recently been developed. SINEUP allows scientists, for the first time, to target individual genes in cells to knockup, or increase, the amount of protein they make. The technique will improve Protein manufacture, analyse the function of genes and engineer improved cell function.
› Verified 5 days ago
| Entity Name | County Of Robeson Office Of Treasurer |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932287182 PECOS PAC ID: 0345152088 Enrollment ID: O20031103000174 |
News Archive
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.
In the German Center for Infection Research (DZIF), scientists from the universities of Tübingen, Münster and Munich join forces and prepare together with the company Hyglos clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: A highly effective protein from bacteria-specific viruses, so-called bacteriophages, shall rapidly kill the bacteria, which frequently occur in the nose.
The Posey Company, a leader in the design and manufacture of innovative and reliable patient safety solutions, today officially announced the availability of the Posey StaySafe(TM) Bed, Model 8080, for European markets. The bed has been designed for sale in Holland, France, and Germany; sales to additional European country markets will follow.
One of the most innovative biotechnologies of the last decade has recently been developed. SINEUP allows scientists, for the first time, to target individual genes in cells to knockup, or increase, the amount of protein they make. The technique will improve Protein manufacture, analyse the function of genes and engineer improved cell function.
› Verified 5 days ago
| Entity Name | Southeastern Regional Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427282045 PECOS PAC ID: 7012058548 Enrollment ID: O20100106000556 |
News Archive
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.
In the German Center for Infection Research (DZIF), scientists from the universities of Tübingen, Münster and Munich join forces and prepare together with the company Hyglos clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: A highly effective protein from bacteria-specific viruses, so-called bacteriophages, shall rapidly kill the bacteria, which frequently occur in the nose.
The Posey Company, a leader in the design and manufacture of innovative and reliable patient safety solutions, today officially announced the availability of the Posey StaySafe(TM) Bed, Model 8080, for European markets. The bed has been designed for sale in Holland, France, and Germany; sales to additional European country markets will follow.
One of the most innovative biotechnologies of the last decade has recently been developed. SINEUP allows scientists, for the first time, to target individual genes in cells to knockup, or increase, the amount of protein they make. The technique will improve Protein manufacture, analyse the function of genes and engineer improved cell function.
› Verified 5 days ago
| Entity Name | Unc Physicians Network Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750704367 PECOS PAC ID: 5496940546 Enrollment ID: O20101115000646 |
News Archive
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.
In the German Center for Infection Research (DZIF), scientists from the universities of Tübingen, Münster and Munich join forces and prepare together with the company Hyglos clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: A highly effective protein from bacteria-specific viruses, so-called bacteriophages, shall rapidly kill the bacteria, which frequently occur in the nose.
The Posey Company, a leader in the design and manufacture of innovative and reliable patient safety solutions, today officially announced the availability of the Posey StaySafe(TM) Bed, Model 8080, for European markets. The bed has been designed for sale in Holland, France, and Germany; sales to additional European country markets will follow.
One of the most innovative biotechnologies of the last decade has recently been developed. SINEUP allows scientists, for the first time, to target individual genes in cells to knockup, or increase, the amount of protein they make. The technique will improve Protein manufacture, analyse the function of genes and engineer improved cell function.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Donald Randolph Mckinley, MD 5221 Paramount Pkwy Ste 220, Morrisville, NC 27560-5490 Ph: () - | Donald Randolph Mckinley, MD 4300 Fayetteville Rd, Lumberton, NC 28358-2677 Ph: (910) 608-3078 |
News Archive
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.
In the German Center for Infection Research (DZIF), scientists from the universities of Tübingen, Münster and Munich join forces and prepare together with the company Hyglos clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: A highly effective protein from bacteria-specific viruses, so-called bacteriophages, shall rapidly kill the bacteria, which frequently occur in the nose.
The Posey Company, a leader in the design and manufacture of innovative and reliable patient safety solutions, today officially announced the availability of the Posey StaySafe(TM) Bed, Model 8080, for European markets. The bed has been designed for sale in Holland, France, and Germany; sales to additional European country markets will follow.
One of the most innovative biotechnologies of the last decade has recently been developed. SINEUP allows scientists, for the first time, to target individual genes in cells to knockup, or increase, the amount of protein they make. The technique will improve Protein manufacture, analyse the function of genes and engineer improved cell function.
› Verified 5 days ago
Christine Marie Mellon, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 725 Oakridge Blvd, Suite C-1, Lumberton, NC 28358 Phone: 910-738-9601 Fax: 910-671-8261 | |
Dr. Larry A Hearne, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 800 Oakridge Blvd, Lumberton, NC 28358 Phone: 910-738-2454 Fax: 910-671-9303 | |
Dr. Edwin L Baker Iii, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 800 Oakridge Blvd, Lumberton, NC 28358 Phone: 910-738-2454 Fax: 910-671-9303 | |
Mr. William Troy Turlington Iv, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 800 Oakridge Blvd, Lumberton, NC 28358 Phone: 910-738-2454 Fax: 910-272-7165 | |
Walter Neal Jr., M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 725 Oakridge Blvd, Ste C-1, Lumberton, NC 28358 Phone: 910-608-3078 Fax: 910-608-3079 | |
Dr. Tawanda B Williams, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 800 Oakridge Blvd, Lumberton, NC 28358 Phone: 910-738-2454 Fax: 910-272-7165 | |
Dr. Lindsey Marie Webb, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 800 Oakridge Blvd, Lumberton, NC 28358 Phone: 910-738-2454 Fax: 910-272-7165 |